BioMarin Pharmaceutical Inc BMRN

US Biotechnology

$60.02 ▼ -0.92% ($-0.56)

📅 Earnings This Week

Open $60.38

Prev Close $60.58

Day Range $58.92 – $60.80

52W Range $49.26 – $66.28

Market Cap $11.60B

P/E (TTM) 43.07

Beta 0.23

EPS (TTM) $1.35

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1999-07-23
Shares Out.	193,280,000
Website	biomarin.com/ ↗
Phone	14155066700
Employees	3,221
Revenue	$766.2M
Gross Profit	$571.2M
Net Income	$105.5M
Free Cash Flow	$767.1M
Total Assets	$8.59B
Total Liabilities	$2.38B
Equity	$6.21B

About BioMarin Pharmaceutical Inc

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

BioMarin Pharmaceutical Inc is a publicly traded company under the ticker symbol BMRN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.